Subscribe To
ABIO / ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study
ABIO News
By Seeking Alpha
May 3, 2022
ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. more_horizontal
By Benzinga
April 1, 2022
ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study
ARCA biopharma IncĀ (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, a more_horizontal